Active	Status	Sponsor type	Region	Phase	Filter
11 Active 10 Inactive 21 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Smith, Angela
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2	Recruiting	3	70	US	RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control	ReGenTree, LLC	Neurotrophic Keratopathy	07/24	11/24
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation Jan 2024 - Dec 2024: Market entry for acute leukemias Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML Dec 2022 - Dec 2022: Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML Data from P1 portion of AUGMENT-101 trial for Leukemia Nov 2022 - Nov 2022: Data from P1 portion of AUGMENT-101 trial for Leukemia Updated data from AUGMENT-101 trial for R/R acute leukemias at ASH 2021 Nov 2021 - Nov 2021: Updated data from AUGMENT-101 trial for R/R acute leukemias at ASH 2021 From P1 portion of P1/2 AUGMENT-101 trial for Leukemia Apr 2021 - Apr 2021: From P1 portion of P1/2 AUGMENT-101 trial for Leukemia Data from AUGMENT-101 trial for AML Dec 2021 - Dec 2020: Data from AUGMENT-101 trial for AML More	Recruiting	1/2	413	Europe, Canada, US, RoW	revumenib, SNDX-5613, cobicistat	Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage	12/27	12/27
FORTIS, NCT04174105: Gene Transfer Study in Patients With Late Onset Pompe Disease	Recruiting	1/2	18	Europe, US	zocaglusagene nuzaparvovec, AT845	Astellas Gene Therapies	Pompe Disease (Late-onset)	11/29	11/29
NCT05045794: Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation	Completed	N/A	219	US	VitaSmart Liver Machine Perfusion System, VitaSmart Liver Machine, Hypothermic oxygenated perfusion, Static cold storage	Bridge to Life Ltd.	End Stage Liver DIsease, Liver Failure	06/24	06/24
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry	Active, not recruiting	N/A	4000	US	Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)	CareDx	Kidney Transplant Rejection	06/25	12/25
Mueller, Dana
No trials found